GlassScriptPhysician profile
Shane Gene Howatt
NPI 1578572152
$5,567.30
in general payments reported to CMS, 2019-2025
31 companies · $823 in 2025
The $823 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,561 · 2022: $841 · 2023: $1,017 · 2024: $1,325 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,164.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $810.70 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $593.32 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $494.79 | 2021-2025 | |
| Glaxosmithkline, LLC. | $469.94 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $428.57 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $377.27 | 2021-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $358.79 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $355.55 | 2021-2025 | Farxiga, Breztri, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $291.08 | 2021-2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $233.41 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.60 | 2023-2025 | Jardiance |
| Amgen INC. | $164.47 | 2021-2025 | Evenity, Prolia, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.62 | 2021-2024 | Xifaxan |
| Abbvie INC. | $100.36 | 2021-2024 | |
| Vifor Pharma, INC. | $87.54 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $62.73 | 2021-2024 | Rexulti |
| Mylan Specialty L.P. | $60.57 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $53.28 | 2021-2022 | |
| Dexcom, INC. | $50.30 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $32.82 | 2023-2024 | Accrufer |
| Amarin Pharma, INC. | $32.69 | 2021 | |
| Merck Sharp & Dohme LLC | $31.75 | 2021 | |
| Abbott Laboratories | $31.46 | 2021-2022 | |
| Viatris Specialty LLC | $29.30 | 2025 | Yupelri |
| Genentech USA, INC. | $24.10 | 2021 | |
| Biogen, INC. | $22.06 | 2021 | |
| Sumitomo Pharma America, INC. | $17.04 | 2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $16.64 | 2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $13.15 | 2022 | |
| Almatica Pharma LLC | $12.70 | 2021 | |
| Currax Pharmaceuticals LLC | $12.70 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Howatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.